Whether BCG strains other than BCG TICE are safe and effective for treating high-grade NMIBC warrants rigorous testing.

Tecentriq combined with BCG did not enhance outcomes for high-risk NMIBC patients compared to BCG alone, with similar event-free survival rates. The ALBAN trial reported higher rates of side effects ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Credit: Johnson & Johnson. Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet. Inlexzo is an intravesical gemcitabine ...

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...

Cretostimogene monotherapy achieves a 75.5% complete response rate in high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients. The treatment maintains a 46% complete response at 12 ...

Intravesical disitamab vedotin (RC48) for patients with HER2-expressing high-risk non-muscle-invasive bladder cancer: A dose-escalation phase I trial. This is an ASCO Meeting Abstract from the 2025 ...

Please provide your email address to receive an email when new articles are posted on . Patients with high-risk non-muscle-invasive bladder cancer who received durvalumab plus BCG had improved DFS.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA ® (nogapendekin alfa inbakicept-pmln) in ...

Inlexzo is an intravesical gemcitabine releasing system that is inserted directly into the bladder through a urinary catheter. The Food and Drug Administration (FDA) has approved Inlexzo ™ ...